Studien

IndikationKurzbezeichnungEudraCT-Nr.PhaseTitel
NHL aggGCT3013-052020-003016-27IIIRandomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.
NHL aggPTLD Registern/an/aNichtinterventionelle, prospektive Registerstudie zur Behandlungspraxis der PTLD in der klinischen Routine
NHL agg.CHART ReviewRegister
NHL agg.ImbruVeR CHOP2015-003429-32Ibrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2
NHL agg.GCT2013-012017-001748-36I - IIA Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013
in Patients with Relapsed, Progressive or Refractory B-Cell
Lymphoma
NHL agg.Daly2, M-2020-3712020-003908-14IIA pivotal Phase II randomised, multi-centre, open-label study to
exalsate the effieacy and safety of MB-CÄRTZ{)19.1 compared ta standard af care therapy in participants ltrith relapsed/refractory: diffuse large B-cell lymphorna (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
NHL agg. MB-CART2019.1, M-2018-3312018-001253-27I - IIA Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHL
NHL agg. DSHNHL 2015-1 , NIVEAU2016-002272-27n/aImprovement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease
NHL agg. Optimate2018-002115-96IIIOptiMATe - Optimizing MATRix as remission induction for PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial“
CLLCLL 172019-003854-99IIIA phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)
CLLCLL FrailIIA PROSPECTIVE, MULTICENTRE PHASE-II TRIAL OF ACALABRUTINIB
IN VERY OLD (>80Y) OR FRAIL PATIENTS WITH CLL
CLLCLL Registern/an/aRegistry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformation
CLLCLL RT12018-002492-17IIA Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG)
MZoLOLYMP-12017-003149-56IIPhase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphoma
MZoLMarginalzonenlymphom-Registern/an/aNicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen
NHL ind.Alternative C2018-004038-13IIA Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
AMLIDH2-Post Allon/an/aEnasidenib as consolidation or salvage therapy for
patients with IDH2 mutated AML or MDS
following allogeneic blood stem cell transplantation
ALLGMALL 08/20132013-003466-13IVTherapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie
ALLALL-Registern/an/aGMALL ALL-Register
MPNIMG-7289-CTP-2012019-003659-13IIA Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
MPNIMG-7289-CTP-2022021-002452-37IIA Multi-Center, Open Label, Extension Study
Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
PNHPNH-Registern/an/aM07-001, 914007 Register für paroxysmale nächtliche Hämoglobinurie (PNH)
PNHCLNP023X22012017-000888-33IIAn open label, single arm, multiple dose study to assess
efficacy, safety, pharmacokinetics and pharmacodynamics
of LNP023 when administered in addition to Standard of
Care (SoC) in patients with paroxysmal nocturnal
hemoglobinuria (PNH) with signs of active hemolysis
PNHBP39144 2016-002128-10I/IIAn adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)
PNHBO42162
Commodore 2 naive
2019-004931-21IIIA phase 3, randomized, open label, active controlles, multicenter study, evaluating the efficacy and safety of Crovalimab versus Eculizumab in Adult and andolescent patients with paroxismal nocturnal Hemoglobinuria not previously treated with complement inhibitors.
PNHAPL2-3072019-001106-23IIIAn Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNHBO42161
Commodore 1 switch
2019-004931-21IIIA Phase III, randomized, open-label, active-controlled, multicenter study evaluating the
efficacy and safety of crovalimab versus eculizumab in adult and adolescent patients
with PNH currently treated with complement inhibitors
PNHCLNP023C123022019-004665-40IIIA randomized, multicenter, active-comparator controlled, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with an intravenous anti-C5 antibody
PNHCLNP023C12301 2020-003172-41IIIA multicenter, single-arm, open-label trial to evaluate efficacy
and safety of oral, twice daily iptacopan in adult PNH patients
who are naive to complement inhibitor therapy
PNHRavuReWon/aIIIAnalysis/Outcomes of Patients who switched from being under eculizumab
to ravulizumab treatment in a real-world setting – according to the label
but not included in Phase 3 studies
RavuReWo
AnämieMOM-M281-0062019-000720-17II - IIIEfficacy and Safety of M281 in Adults with Warm Autoimmune
Hemolytic Anemia: A Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Study with a Long-term Open-label
Extension
AnämieEMAA 93452014-000174-19II - IIIEfficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A
AnämieC-935788-058 (Extension)2019-001882-34IIIA Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
CADPDY16370
BIVV020
2019-001844-221bA multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin disease
CADACT168322020‐003880‐241b - IIA multicenter, open-label, Phase 1b/2 study to evaluate the safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in patients with primary warm autoimmune hemolytic anemia
CADLTS166372019-004423-211bAn open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with BIVV020
ITPARGX-113-18032019-002100-41IIIA Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia
ITPARGX-113-18012019-002100-41IIIA Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia
ITPPDY168942020-00416-18IiaA multicenter, phase 2a, open label, nonrandomized study
evaluating the efficacy, safety, and tolerability of BIVV020 in
adults with chronic immune thrombocytopenia (ITP)”
ITP / CADCLNP023L122012021-002039-40IIAn open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan(LNP023) in participants with autoimmune benignhematological disorders
WaihaANX-wAIHA-01n/an/a“A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia “
MMRegeneron 5458-ONC-1826n/aI - IIPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3
BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR
REFRACTORY MULTIPLE MYELOMA
MM GMMG-CONCEPT2016-000432-17IIEine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms
AL-AmyloidoseCAEL301-3012019‐004254‐28IIIA Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
AL-AmyloidoseCAEL301-3022020-000713-32IIIA Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
AL-AmyloidoseAmyloidose Registern/an/aNationales klinisches Amyloidose-Register

Liebe Patientinnen und Patienten,

aufgrund des seit dem 4. Mai 2022 andauernden Streiks der Gewerkschaft Ver.di an allen Universitätskliniken in Nordrhein-Westfalen kommt es aktuell auch am Universitätsklinikum Essen und in unserer Klinik zu Verzögerungen im Betrieb. Die Sicherheit und Gesundheit unserer Patientinnen und Patienten hat dabei für uns alle die höchste Priorität.

Um die medizinische Versorgung der Patientinnen und Patienten der Klinik für Hämatologie und Stammzelltransplantation zu sichern werden ambulante Patientinnen und Patienten ohne dringliche Vorstellung gebeten angebotene spätere Termine zur ambulanten Vorstellung wahrzunehmen. Sie werden dazu von uns telefonisch kontaktiert.

Wir bitten um Ihr Verständnis!

Aufgrund der aktuellen Entwicklung des Pandemiegeschehens gilt in der Klinik für Hämatologie und Stammzelltransplantation bis auf weiteres ein generelles Besuchsverbot!

Zugang zur Klinik nur mit ausgefülltem » Gesundheitsfragebogen (auch vor Ort möglich)
Access to the clinic only with a completed » health questionnaire (also possible on site)